Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study

Fabiano G. Nery, Emel S. Monkul, John P. Hatch, Manoela Fonseca, Giovana B. Zunta-Soares, Benício N. Frey, Charles L. Bowden, Jair C. Soares

Research output: Contribution to journalArticle

206 Citations (Scopus)

Abstract

Objective: To investigate whether the cox-2 inhibitor celecoxib has antidepressant effects in bipolar disorder (BD) patients during depressive or mixed phases. Methods: We studied 28 DSM-IV BD patients who were experiencing a depressive or mixed episode and were on a stable dose of a mood stabilizer or atypical antipsychotic medication. Subjects were randomized to receive 6 weeks of double-blind placebo or celecoxib (400mg/day) treatment. Current mood stabilizer or antipsychotic medication remained at the same doses during the trial. Results: Intention-to-treat analysis showed that the patients receiving celecoxib had lower Hamilton Depression Rating Scale (HamD) scores after 1 week of treatment compared to the patients receiving placebo, but this difference was not statistically significant (p = 0.09). The improvement in the first week of treatment was statistically significant when the analysis included only the subjects who completed the full 6-week trial (p = 0.03). The two groups did not differ significantly on depressive or manic symptoms from the second week until the end of the trial. Celecoxib was well tolerated with the exception of two subjects who dropped out of the study due to rash. Conclusions: Our findings suggest that adjunctive treatment with celecoxib may produce a rapid-onset antidepressant effect in BD patients experiencing depressive or mixed episodes.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalHuman Psychopharmacology
Volume23
Issue number2
DOIs
StatePublished - Mar 2008

Fingerprint

Celecoxib
Bipolar Disorder
Placebos
Antidepressive Agents
Antipsychotic Agents
Therapeutics
Intention to Treat Analysis
Exanthema
Diagnostic and Statistical Manual of Mental Disorders
Depression

Keywords

  • Anti-inflammatory agents
  • Bipolar depression
  • Bipolar disorder
  • Celecoxib
  • Cyclooxygenase-2 inhibitors
  • Randomized-controlled trials

ASJC Scopus subject areas

  • Pharmacology
  • Psychology(all)
  • Neuroscience(all)
  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neurology
  • Clinical Neurology

Cite this

Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder : A double-blind, randomized, placebo-controlled study. / Nery, Fabiano G.; Monkul, Emel S.; Hatch, John P.; Fonseca, Manoela; Zunta-Soares, Giovana B.; Frey, Benício N.; Bowden, Charles L.; Soares, Jair C.

In: Human Psychopharmacology, Vol. 23, No. 2, 03.2008, p. 87-94.

Research output: Contribution to journalArticle

Nery, FG, Monkul, ES, Hatch, JP, Fonseca, M, Zunta-Soares, GB, Frey, BN, Bowden, CL & Soares, JC 2008, 'Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study', Human Psychopharmacology, vol. 23, no. 2, pp. 87-94. https://doi.org/10.1002/hup.912
Nery, Fabiano G. ; Monkul, Emel S. ; Hatch, John P. ; Fonseca, Manoela ; Zunta-Soares, Giovana B. ; Frey, Benício N. ; Bowden, Charles L. ; Soares, Jair C. / Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder : A double-blind, randomized, placebo-controlled study. In: Human Psychopharmacology. 2008 ; Vol. 23, No. 2. pp. 87-94.
@article{d74cad49cb4844b0813d3432fb6901df,
title = "Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study",
abstract = "Objective: To investigate whether the cox-2 inhibitor celecoxib has antidepressant effects in bipolar disorder (BD) patients during depressive or mixed phases. Methods: We studied 28 DSM-IV BD patients who were experiencing a depressive or mixed episode and were on a stable dose of a mood stabilizer or atypical antipsychotic medication. Subjects were randomized to receive 6 weeks of double-blind placebo or celecoxib (400mg/day) treatment. Current mood stabilizer or antipsychotic medication remained at the same doses during the trial. Results: Intention-to-treat analysis showed that the patients receiving celecoxib had lower Hamilton Depression Rating Scale (HamD) scores after 1 week of treatment compared to the patients receiving placebo, but this difference was not statistically significant (p = 0.09). The improvement in the first week of treatment was statistically significant when the analysis included only the subjects who completed the full 6-week trial (p = 0.03). The two groups did not differ significantly on depressive or manic symptoms from the second week until the end of the trial. Celecoxib was well tolerated with the exception of two subjects who dropped out of the study due to rash. Conclusions: Our findings suggest that adjunctive treatment with celecoxib may produce a rapid-onset antidepressant effect in BD patients experiencing depressive or mixed episodes.",
keywords = "Anti-inflammatory agents, Bipolar depression, Bipolar disorder, Celecoxib, Cyclooxygenase-2 inhibitors, Randomized-controlled trials",
author = "Nery, {Fabiano G.} and Monkul, {Emel S.} and Hatch, {John P.} and Manoela Fonseca and Zunta-Soares, {Giovana B.} and Frey, {Ben{\'i}cio N.} and Bowden, {Charles L.} and Soares, {Jair C.}",
year = "2008",
month = "3",
doi = "10.1002/hup.912",
language = "English (US)",
volume = "23",
pages = "87--94",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder

T2 - A double-blind, randomized, placebo-controlled study

AU - Nery, Fabiano G.

AU - Monkul, Emel S.

AU - Hatch, John P.

AU - Fonseca, Manoela

AU - Zunta-Soares, Giovana B.

AU - Frey, Benício N.

AU - Bowden, Charles L.

AU - Soares, Jair C.

PY - 2008/3

Y1 - 2008/3

N2 - Objective: To investigate whether the cox-2 inhibitor celecoxib has antidepressant effects in bipolar disorder (BD) patients during depressive or mixed phases. Methods: We studied 28 DSM-IV BD patients who were experiencing a depressive or mixed episode and were on a stable dose of a mood stabilizer or atypical antipsychotic medication. Subjects were randomized to receive 6 weeks of double-blind placebo or celecoxib (400mg/day) treatment. Current mood stabilizer or antipsychotic medication remained at the same doses during the trial. Results: Intention-to-treat analysis showed that the patients receiving celecoxib had lower Hamilton Depression Rating Scale (HamD) scores after 1 week of treatment compared to the patients receiving placebo, but this difference was not statistically significant (p = 0.09). The improvement in the first week of treatment was statistically significant when the analysis included only the subjects who completed the full 6-week trial (p = 0.03). The two groups did not differ significantly on depressive or manic symptoms from the second week until the end of the trial. Celecoxib was well tolerated with the exception of two subjects who dropped out of the study due to rash. Conclusions: Our findings suggest that adjunctive treatment with celecoxib may produce a rapid-onset antidepressant effect in BD patients experiencing depressive or mixed episodes.

AB - Objective: To investigate whether the cox-2 inhibitor celecoxib has antidepressant effects in bipolar disorder (BD) patients during depressive or mixed phases. Methods: We studied 28 DSM-IV BD patients who were experiencing a depressive or mixed episode and were on a stable dose of a mood stabilizer or atypical antipsychotic medication. Subjects were randomized to receive 6 weeks of double-blind placebo or celecoxib (400mg/day) treatment. Current mood stabilizer or antipsychotic medication remained at the same doses during the trial. Results: Intention-to-treat analysis showed that the patients receiving celecoxib had lower Hamilton Depression Rating Scale (HamD) scores after 1 week of treatment compared to the patients receiving placebo, but this difference was not statistically significant (p = 0.09). The improvement in the first week of treatment was statistically significant when the analysis included only the subjects who completed the full 6-week trial (p = 0.03). The two groups did not differ significantly on depressive or manic symptoms from the second week until the end of the trial. Celecoxib was well tolerated with the exception of two subjects who dropped out of the study due to rash. Conclusions: Our findings suggest that adjunctive treatment with celecoxib may produce a rapid-onset antidepressant effect in BD patients experiencing depressive or mixed episodes.

KW - Anti-inflammatory agents

KW - Bipolar depression

KW - Bipolar disorder

KW - Celecoxib

KW - Cyclooxygenase-2 inhibitors

KW - Randomized-controlled trials

UR - http://www.scopus.com/inward/record.url?scp=40549126636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40549126636&partnerID=8YFLogxK

U2 - 10.1002/hup.912

DO - 10.1002/hup.912

M3 - Article

C2 - 18172906

AN - SCOPUS:40549126636

VL - 23

SP - 87

EP - 94

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 2

ER -